VACOP-B (Etoposide/Doxorubicin/Cyclophosphamide/Vincristine/Prednisolone/Bleomycin) Combination Chemotherapy for the Treatment of Intermediate and High Grade Non-Hodgkin's Lymphoma.
- Author:
Young Im KWAK
1
;
Young Kug CHEON
;
Young Hyuck IM
;
Yoon Koo KANG
;
Soon Nam LEE
;
Jhin Oh LEE
;
Tae Woong KANG
Author Information
1. Department of Internal Medicine, Korea Cancer Center Hospital, Korea.
- Publication Type:Original Article
- Keywords:
VACOP-B;
Chemotherapy;
Non-Hodgkin's lymphoma
- MeSH:
Cyclophosphamide;
Disease-Free Survival;
Drug Therapy;
Drug Therapy, Combination*;
Follow-Up Studies;
Heart Failure;
Hodgkin Disease;
Humans;
Leukopenia;
Lymphoma, Non-Hodgkin*;
Nausea;
Peripheral Nervous System Diseases;
Stomatitis;
Survival Rate;
Thrombocytopenia;
Vomiting
- From:Journal of the Korean Cancer Association
1997;29(1):146-159
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To determine the antitumor activity of VACOP-B regimen for advanced non- Hodgkin's lymphoma (NHL) in terms of complete response rate, disease free survival, and overall survival, to assess the toxicities of this regimen, and to analyze the prognostic factors influencing the treatment results.Patients and methods: Between Apr. 1991 and Aug. 1993, thirty-six previously untreated patients with the intermediate or high grade NHL were treated with VACOP-B (etoposide/doxorubicin/cyclophosphamide/vincristine/prednisolone/bleomycin) combination chemotherapy. In case of initial bulky disease or residual disease after chemotherapy, radiation therapy of involved field was added. RESULTS: Complete response (CR) was achieved in 69% (25/36) of the eligible patients after VACOP-B chemotherapy, and 5 of 11 patients who remained in partial response (PR) after chemotherapy achieved CR after additional radiation therapy of involved field, resulting in 83% (30/36) of CR rate. With a median follow-up of 47.2 months, the disease free survival was 1~42.1+ months, and its median was 24 months. The range of survival time was 7~49.1+ months, and the median survival time was not reached at this time. The projected 3-year survival rate was 70%. Leukopenia was observed in 43% of chemotherapy cycles and thrombocytopenia in 2.3%. However, no treatment-related death was observed. For non-hematologic toxicities, nausea and vomiting were observed in 58% of patients, stomatitis in 58%, peripheral neuropathy in 58%, pulmonary toxicity in 3% and congestive heart failure in 3%. These toxicities were tolerable and all reversible. The prognostic factors influencing the complete response rate were performance status of patient (p=0.026) and relative dose intensity of cyclophosphamide (p=0.013). CONCLUSION: VACOP-B regimen is an effective and tolerable regimen for the intermediate and high grade NHL. And long term follow-up and phase III study will be needed for evaluation of these results compared to previous other treatment modality.
